The usefulness of anticholinergic drug to chronic heart failure patients with chronic obstructive pulmonary disease

The usefulness of anticholinergic drug to chronic heart failure patients with chronic obstructive pulmonary disease - Anticholinergic drug for CHF with COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027228

Enrollment

300

Registered

2017-05-10

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure with chronic obstructive pulmonary disease

Interventions

Tiotropium:150 Period:2014.6-2018.3 No treatment:150 Period:2014.6-2018.3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Chronic heart failure with chronic obstructive pulmonary disease 2.Stable outpatients(NYHA I-III)

Exclusion criteria

Exclusion criteria: 1.severe chronic obstructive pulmonary disease 2.acute heart failure patients or acute myocardial infarction patients 3.History and concurrent medical conditions Having bronchial asthma Having pulmonary fibrosis definitely 4.Patients who had already drugs for COPD 5.Patents with hypersensitivity of study drug 6.Women who are pregnant, lactating 7.Patients who have been judged ineligible for the study by the investigator

Design outcomes

Primary

Measure	Time frame
Cardiac death and rehospitalization due to worsening heart failure	—

Secondary

Measure	Time frame
Index of respiratory function test(FVC, FEV1, FEV1%) Questionnaires (CAT, mMRC questionnaire) Laboratory test	—

Countries

Japan

Contacts

Public ContactAtsushi Kobayashi

Fukushima Medical University Department of Cardiology and Hematology

koba-a@fmu.ac.jp024-547-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026